Eculizumab is not a licensed treatment for Dense Deposit Disease and well-constructed clinical trials on effectiveness are yet to be carried out. A new policy proposition for its use in treating the disease before a patient has had a kidney transplant will be considered during 2016/17.
There is a published policy on use of this drug for the prevention of recurrence after a patient has had a transplant. A policy on the treatment of C3 glomerulopathy that occurs after a kidney transplant will be considered by the Clinical Priorities Advisory Group (CPAG) at its next meeting. The CPAG reviews both patient benefits and cost considerations when making recommendations.